头颈部鳞状细胞癌首次治疗后FDG-PET/CT中NI-RADS 2类的阴性预测值
回顾性纳入2008至2016年在本机构接受根治性放化疗或放疗的头颈部鳞状细胞癌患者,首次治疗后FDG-PET/CT表现为病变明显改善但原发瘤床或淋巴结有轻度残留肿块或FDG摄取(NI-RADS 2类)者,以2年无病生存为参考标准,阴性预测值为85%(95%CI 77%-90%),低于初始完全缓解者的91%。
要点
- NI-RADS 2类(病变明显改善但原发瘤床或淋巴结有轻度残留肿块或FDG摄取)首次治疗后FDG-PET/CT的阴性预测值为85%(95%CI 77%-90%)。
- 110例中17例(15%)在治疗完成后2年内出现局部区域治疗失败。
- 肿瘤复发最常见部位为颈部淋巴结(59%),治疗完成至治疗失败的中位时间间隔为10个月(范围5-24个月)。
核心结论
- 在头颈部鳞状细胞癌治疗后不完全缓解的患者中,首次治疗后FDG-PET/CT的阴性预测值为85%,低于初始完全缓解患者的91%;作者认为NI-RADS 2类患者应比初始完全缓解(NI-RADS 1类)患者接受更频繁的临床和影像监测。
研究设计与样本
- 回顾性研究,纳入2008至2016年在本机构接受根治性放化疗或放疗的头颈部鳞状细胞癌患者共110例,首次治疗后FDG-PET/CT判读为NI-RADS 2类,以2年无病生存为参考标准,采用Newcombe法计算阴性预测值及95%CI。
关键影像表现/征象
- 首次治疗后FDG-PET/CT表现为病变明显改善,但原发瘤床或淋巴结有轻度残留肿块或FDG摄取,判读为NI-RADS 2类。
- 肿瘤复发最常见部位为颈部淋巴结(59%)。
诊断标准与关键数值
- NI-RADS 2类定义为首次治疗后FDG-PET/CT示病变明显改善但原发瘤床或淋巴结有轻度残留肿块或FDG摄取。
- NI-RADS 2类患者首次治疗后FDG-PET/CT的阴性预测值为85%(95%CI 77%-90%),参考标准为2年无病生存。
- 初始完全缓解(NI-RADS 1类)患者FDG-PET/CT的阴性预测值为91%。
临床应用与阅片要点
- 作者认为,NI-RADS 2类(不完全缓解)患者应比初始完全缓解(NI-RADS 1类)患者接受更频繁的临床和影像监测。
- 判读首次治疗后FDG-PET/CT时,原发瘤床或淋巴结的轻度残留肿块或FDG摄取归为NI-RADS 2类,其阴性预测值为85%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: FDG PET/CT has a high negative predictive value in patients with head and neck squamous cell carcinoma who responds completely to non-operative therapy. However, the treatment failure rate in patients with a partial but incomplete response is unclear. Our aim was to investigate the negative predictive value of the first posttreatment FDG-PET/CT in patients with head and neck squamous cell carcinoma with incomplete response interpreted as Neck Imaging Reporting and Data System (NI-RADS) category 2.
MATERIALS AND METHODS: We retrospectively identified patients with head and neck squamous cell carcinoma treated with chemoradiation or radiation therapy with curative intent in our institution between 2008 and 2016. We included patients whose first posttreatment FDG-PET/CT was interpreted as showing marked improvement of disease but who had a mild residual mass or FDG avidity in either the primary tumor bed or lymph nodes (NI-RADS 2). The negative predictive value of FDG-PET/CT was calculated, including the 95% CI, using the Newcombe method. Two-year disease-free survival was the reference standard.
RESULTS: Seventeen of 110 patients (15%) experienced locoregional treatment failure within 2 years of completing treatment, yielding a negative predictive value of 85% (95% Cl, 77%-90%). The most common location of tumor recurrence was the cervical lymph nodes (59%). The median time interval between completion of therapy and treatment failure was 10 months (range, 5-24 months).
CONCLUSIONS: In patients with an incomplete response after treatment of head and neck squamous cell carcinoma, the negative predictive value of the first posttreatment FDG-PET/CT was 85%, which is lower than the 91% negative predictive value of FDG-PET/CT in patients with an initial complete response. Patients with an incomplete response (NI-RADS 2) should undergo more frequent clinical and imaging surveillance than patients with an initial complete response (NI-RADS 1).
引用
- Wangaryattawanich P, Branstetter BF, Hughes M, et al. Negative Predictive Value of NI-RADS Category 2 in the First Posttreatment FDG-PET/CT in Head and Neck Squamous Cell Carcinoma. AJNR Am J Neuroradiol. 2018. PMID: 30166429. doi:10.3174/ajnr.A5767
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。